Company: GEHC
Filing Date: 2025-04-30
Form Type: 10-Q
Source: 0001932393-25-000014
Chunk: 32

Company: GE HealthCare Technologies Inc.
Filing Date: 2025-04-30
Form: 10-Q
Item: Item 8
Chunk 32
---
    773785(2)%Total revenues    $4,777$4,6503%

For the three months ended March 31, 2025

Total revenues were $4,777 million, growing 3% as reported and 4% organically*. Sales of products increased 2% or $71 million with strong growth in USCAN, led by PDx and Imaging segment revenues. Sales of services increased 3% or $56 million primarily driven by growth in new and existing customer contractual agreements.

____________________

*Non-GAAP Financial Measure

29

Table of Contents                 

The segment revenues were as follows:

•Imaging segment revenues were $2,140 million, growing 4% or $77 million, with growth across all regions, led by Molecular Imaging and Computed Tomography (“MI/CT”) and Magnetic Resonance (“MR”) product lines;

•AVS segment revenues were $1,239 million, growing 1% or $12 million, with strength in the U.S. market largely offset by unfavorable foreign currency impacts and continued pressure in the China market.

•PCS segment revenues were $753 million, growing 1% or $6 million, driven by strength in the U.S., including growth in Monitoring Solutions, largely offset by declines in Anesthesia revenues due to market timing and unfavorable foreign currency impacts; and

•PDx segment revenues were $632 million, growing 6% or $33 million driven by continued growth in price and volume.

The regional revenues were as follows:

•USCAN revenues were $2,237 million, growing 7% or $143 million with growth across all segment revenues, led by strong growth in PDx and Imaging revenues;

•EMEA revenues were $1,174 million, flat to the prior year, with growth in PDx and Imaging revenues offset by unfavorable foreign currency impacts;

•China region revenues were $593 million, decreasing 1% or $4 million due to a decrease in AVS revenues and unfavorable foreign currency impacts, largely offset by growth in PDx and Imaging revenues; and

•Rest of World revenues were $773 million, decreasing 2% or $12 million due to unfavorable foreign currency impacts, partially offset by growth in Imaging revenues.

OPERATING INCOME, NET INCOME ATTRIBUTABLE TO GE HEALTHCARE, ADJUSTED EBIT*, AND ADJUSTED NET INCOME*.

For the three months ended March 312025% of Total revenues2024% of Total revenues